Episodes
-
Host: Diana V. Do, MD
Guest: Peter K. Kaiser, MD
This case consult with Dr Do and Dr Kaiser will consider a treatment-experienced patient referred for a 2nd opinion with decreased vision and prior diagnosis of neovascular AMD (nAMD). Dr Do and Dr Kaiser will discuss the recently approved anti-vascular endothelial growth factor (VEGF) agents with greater durability and longer dosing intervals that can decrease treatment burden. These retina specialists will evaluate the treatment responses in this patient and discuss whether to modify dosing intervals or switch therapies. This case illustrates the burden of care for patients with neovascular AMD (nAMD), and shows how to use the more durable anti-VEGF therapies in clinical practice to reduce treatment burden.
-
Host: Jennifer I. Lim, MD, FARVO
Guest: Carl Regillo, MD
What evidence do we have that blocking Ang-2 and VEGF-A is beneficial for patients? Tune in to hear Dr. Jennifer Lim and Dr. Carl Regillo examine the anatomical and biomarker evidence surrounding dual inhibition of Ang-2 and VEGF-A. Find out how bispecific targeting can benefit patients with neovascular age-related macular degeneration and diabetic macular edema.
-
Missing episodes?
-
Host: Carl Regillo, MD
Guest: Jennifer I. Lim, MD, FARVO
What are the biomarkers that indicate dual targeting helps to reduce vascular leakage and suppress neovascularization? Join Dr. Carl Regillo and Dr. Jennifer Lim as they discuss the biomarkers of Ang-2 and VEGF-A suppression. Hear how to achieve earlier and faster fluid resolution in both neovascular age-related macular degeneration and diabetic macular edema.
-
Guest: Durga Borkar, MD, MMCi
Guest: Diana V. Do, MD
Guest: Peter K. Kaiser, MD
The CME News Broadcast webinar will engage retina specialists and treating ophthalmologists with education needed to integrate the new durable anti-vascular endothelial growth factor (VEGF) therapies for neovascular AMD (nAMD) into clinical practice. This will include recent data on the efficacy, safety, and durability of these new therapies and the imaging approaches that can be used to facilitate monitoring of nAMD disease progression and treatment success. This activity will create understanding of the new durable therapies and how they can extend dosing intervals. The expert faculty will discuss the latest data on new anti-VEGF therapies with the potential to reduce treatment burden and improve vision outcomes.
-
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Arghavan Almony, MD
The production of biosimilar therapies is setting the stage for a shift in how we approach treating patients with wet AMD, diabetic retinopathy, macular edema, and other retinal diseases, but many questions remain regarding how their efficacy and safety compare to the reference products and how we can best talk to our patients about these treatment options. To help shed light on these and other FAQs, Dr. Mary Katherine Cheeley speaks with Dr. Arghavan Almony, Adjunct Assistant Professor at Wallace School of Osteopathic Medicine at Campbell University in North Carolina.
-
Host: Jennifer Caudle, DO
Guest: Anne Negrin, MD
Since eye issues are becoming increasingly common in patients with rheumatological conditions, it’s now more vital than ever that physicians are aware of their common symptoms. Joining Dr. Jennifer Caudle is Dr. Anne Negrin, an ophthalmologist in New York, to break down these symptoms and to focus on rheumatological concerns that ophthalmologists see in practice.
-
Host: Jennifer Caudle, DO
Guest: Jean Bennett, MD, PhD
Guest: Albert Maguire, MD
Power couple Drs. Jean Bennett and Albert Maguire discuss how their new therapy for the RPE65 gene, which causes retinal blindness, was recently approved by the FDA to become the first gene therapy treatment for a genetic disease in the United States and the first worldwide treatment for inherited blindness. Not only do they delve into the mechanics of the corrected gene injection, but they also explain what this milestone means for patient eligibility and how their marriage has played a role in the success of their research partnership.
Dr. Jean Bennett is the F.M. Kirby Professor of Ophthalmology at the Perelman School of Medicine at the University of Pennsylvania, and Dr. Albert Maguire is a Professor of Ophthalmology at the Hospital of the University of Pennsylvania and Attending Physician in the Division of Pediatric Ophthalmology at Children’s Hospital of Philadelphia.
-
[Read the Article]
Proliferative diabetic retinopathy (PDR) is a leading cause of vision loss in patients with diabetes, resulting in up to 24,000 cases of blindness each year in the United States. Laser therapy has been the most common treatment used to help reduce severe vision loss, but the procedure has many side effects including permanent loss of peripheral vision and swelling of the retina.
A group of researchers from across the US tested an alternative treatment using an injectable medication called ranibizumab, to see if it would be as effective as the laser therapy. They studied more than 300 patients with PDR, assigning them to either receive standard laser therapy or an injection into the eye. In total, they treated close to 400 eyes.
Outcomes, especially loss of vision, were compared at two years. Over the two year period, researchers found that patients receiving the injections of medication had fewer side effects and did somewhat better in terms of vision loss than those who received laser therapy.[Watch more videos of The JAMA Report]
-
Host: Jennifer Caudle, DO
Dr. Jennifer Caudle welcomes Dr. Patrick Spencer, Chairman of the Department of Ophthalmology at Grandview Medical Center in Dayton, Ohio. Their discussion centers on primary care manifestations of sickle cell retinopathy, from early to late-stage presentations and the gold standard treatment approaches along this disease course.
-
Host: Brian P. McDonough, MD, FAAFP
Dr. Brian McDonough welcomes Dr. Gail L. Torkildsen, staff ophthalmologist at Andover Eye Associates and one of the leading Dry Eye Principal Investigators in the world. Dr. Torkildsen has served as P.I. on over 20 client-sponsored Dry Eye studies since 2002. In this discussion she takes listeners on a tour of common eye problems faced in primary care, and how clinicians can better prepare themselves to address issues such as Meibobian gland disorders, blepharitis, dry eyes, and conjunctivitis with greater confidence.
-
Host: Brian P. McDonough, MD, FAAFP
A clinical pearl in the arena of eye care is that serious eye problems tend to manifest serious symptoms and signs, which makes vision loss one of the key findings in a diagnostic workup. Yet vision testing is commonly neglected in primary care practice even when patients present with eye-related complaints. What are the most important steps a clinician can take when assessing eye problems, and where does the primary care practitioner fit into the ophthalmologic care continuum? Dr. Brian McDonough welcomes Dr. Sumitra Khandelwal, Assistant Professor of Ophthalmology at Baylor College of Medicine, to examine the top issues in eye care for generalists and ophthalmic specialists.
-
Host: Brian P. McDonough, MD, FAAFP
On average, more than 90% of adults spend more than two hours each day using a digital device, and for 60% of the population, that daily use pattern extends beyond five hours. Regardless of the reasons why, all that time can take a toll on the eyes and lead to digital eye strain. Speaking on the health implications of digital eye strain is Dr. Dora Adamopolous, optometrist in practice in Alexandia, VA.
-
Guest: Stephen Orlin, MD
This Excerpt from the Podium comes from Prova Education's "From Guidelines to Practice" program in New York City and features Dr. Stephen Orlin, Associate Professor of Ophthalmology at the University of Pennsylvania School of Medicine. Dr. Orlin speaks on the various types of conjunctivitis, their common etiologies, and their respective management approaches.
-
Guest: Stephen Orlin, MD
This Excerpt from the Podium features Dr. Stephen Orlin, Associate Professor of Ophthalmology at the University of Pennsylvania School of Medicine, speaking on the patient workup for red eye at Prova Education's "From Guidelines to Practice" program in New York City.
-
Guest: Stephen Orlin, MD
The classic "red eye" presentation by your patient may be a common sighting in your clinical practice, but are you truly up to date on the various causes, treatments, and pitfalls that clinicians encounter when confronting ocular problems? Discussing this issue is Dr. Stephen Orlin, Associate Professor of Ophthalmology, Director of the Cornea Department, and Co-Director of the Refractive Surgery Service at the University of Pennsylvania.
-
Host: Lee Freedman, MD
Guest: Jean Bennett, MD, PhD
Host Dr. Lee Freedman and Dr. Jean Bennett, the FM Kirby Professor of Epistemology at the University of Pennsylvania School of Medicine, explore how the study of molecular genetics of inherited retinal degenerations can help develop treatments for congenital eye disorders, as well as adult-onset diseases and possibly disorders that affect the body outside the eye.
-
Host: Steven Edelman, MD
Guest: Azza El-Remessy, PhD, RPh
Retinopathy is one of the most common complications for patients living with diabetes but there are few treatment options and no early-stage interventions. How is research helping to pinpoint potential targets for early intervention and a possible oral treatment? Join host Dr. Steven Edelman and his guest, assistant professor and director of clinical and experimental therapeutics at the University of Georgia, Dr. Azza El-Remessy, as they discuss the latest research into the potential of statins to prevent diabetic-related blindness.
-
Host: Roy Levit, MD
Guest: Alan Ruby, MD
The standard treatment for proliferative and non-proliferative diabetic retinopathy is laser photocoagulation, but novel methods, including injectable steroids or anti-vascular endothelial growth factor, are also showing promise. What tests can help opthamologists determine the area of leakage in the eye that needs treatment? How soon after surgery will patients see a change in their vision? Dr. Alan Ruby, opthamologist and clinical assistant professor of biomedical sciences at the Eye Research Institute at Oakland University, in Rochester, Michigan, discusses ways to maximize the overall visual outcome for patients with diabetic retinopathy. How can diabetic retinopathy be prevented? Dr. Roy Levit hosts.
-
Host: Roy Levit, MD
Guest: Alan Ruby, MD
The eyes can yield clues to vascular issues elsewhere in the body. How can the two forms of diabetic retinopathy, which are non-proliferative and proliferative, affect vision, and how might retinopathy be associated with somatic effects resulting from diabetes? Dr. Alan Ruby, opthamologist and clinical assistant professor of biomedical sciences at the Eye Research Institute at Oakland University, in Rochester, Michigan, discusses the correlation between diabetic retinopathy and complications throughout the body. Can tight control of diabetes affect the progression or regression of retinopathy? What can physicians caring for patients with diabetes do to identify vision changes early on, and potentially reduce the risk of later complications? Dr. Roy Levit hosts.
-
Host: Roy Levit, MD
Guest: Saad Shaikh, MD
Although floaters in one's vision are common, this symptom can be a key indicator of a retinal tear or detachment. What is the incidence of retinal detachment in the U.S., and when should a primary care physician suspect this condition? Dr. Saad Shaikh, associate professor and member of the teaching faculty at the University of Central Florida College of Medicine in Orlando, and assistant professor at the University of South Florida, College of Medicine and at the Florida State College of Medicine, discusses the development of retinal detachments, risk factors, and the techniques used to correct the condition. Dr. Roy Levit hosts.
- Show more
